INT273005

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.07
First Reported 2003
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 2.40
Pain Relevance 0.38

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL33) extracellular region (IL33)
IL33 (Homo sapiens)
Pain Link Frequency Relevance Heat
Desipramine 6 93.48 High High
Duloxetine 24 91.36 High High
Inflammation 4 86.48 High High
abdominal pain 1 79.04 Quite High
Bioavailability 2 63.32 Quite High
Pain 12 29.76 Quite Low
Neurotransmitter 2 27.36 Quite Low
Dopamine 6 22.44 Low Low
cva 4 21.60 Low Low
sSRI 28 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 12 98.56 Very High Very High Very High
Hepatitis Virus Infection 2 97.68 Very High Very High Very High
Disease 24 95.52 Very High Very High Very High
Mouth Disease 65 91.76 High High
Hepatitis E Virus Infection 7 91.36 High High
Infection 13 89.20 High High
INFLAMMATION 4 86.48 High High
Jaundice 1 82.24 Quite High
Fever 10 81.44 Quite High
Abdominal Pain 1 79.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Mean decreases in weight for DVS treatment groups were statistically significant compared with baseline and placebo in both high and low dose trials.31–36 In the DVS 400 mg group, there was a statistically significant decrease in weight compared to the DVS 100 mg and 200 mg groups.
Negative_regulation (decreases) of DVS
1) Confidence 0.07 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.16 Pain Relevance 0
These were significantly greater than the increases observed with DVS co-administration (22% and 19%, respectively), suggesting that DVS is not a clinically significant inhibitor of CYP2D6 activity.
Negative_regulation (inhibitor) of DVS
2) Confidence 0.07 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0 Pain Relevance 0.25
Our study will aid in the development of vaccines and, subsequently, specific inhibitors for HEV.


Negative_regulation (inhibitors) of HEV
3) Confidence 0.04 Published 2009 Journal PLoS Pathogens Section Abstract Doc Link PMC2714988 Disease Relevance 1.03 Pain Relevance 0.12
Indeed, the possibility of HEV71 interacting with other enteroviruses in a previous HEV71 epidemic has been raised (14).
Negative_regulation (possibility) of HEV71
4) Confidence 0.03 Published 2003 Journal Emerging Infectious Diseases Section Body Doc Link PMC2873753 Disease Relevance 1.21 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox